Developer docs
API playgroundTry for free, no card

Search company profiles

VectorB2B

Full company profile

uuid003iajk

Namestring
VectorB2B
Legal namestring
VectorB2B – Drug Developing – Association for Research in Biotechnology
Websiteurl
vectorb2b.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

VectorB2B – Drug Developing – Association for Research in Biotechnology is a Lisbon-headquartered, privately constituted Portuguese association (CoLAB) operating as a full-service Contract Research Organisation (CRO). It serves biotechnology and pharmaceutical companies requiring integrated drug development support from preclinical discovery through clinical trials Phase I–IV, as well as Portuguese hospital investigation centres needing embedded study coordination and regulatory support. Its service portfolio covers discovery, GLP/non-GLP toxicology, GMP-certified chemistry manufacturing and controls (with particular strength in biologic medicines and phage therapies), full-service clinical trial management, functional service providing (FSP) for hospitals, R&D portfolio management consulting, and integrated solutions spanning medical devices, animal health, cosmetics, cannabis, and food supplements. The company holds the only GLP-certified in vivo toxicology facility in Portugal and operates a GMP-certified manufacturing plant for Investigational Medicinal Products.

Underlying the service offering is a proprietary clinical trial technology suite (eSuite) comprising CTMS, RTSM, eTMF, EDC, ePRO/eCOA, eConsent, and wearables/device integration, complemented by specialised preclinical platforms including in vivo phage display (via member FASLAB), drug immunogenicity assessment using FO-SPR and cell-based NAb assays, cell-derived and patient-derived xenograft models, and in vivo retinal disease research models. The business model is fee-for-service and managed-service contracts with biotech and pharma sponsors, supplemented by FSP agreements with Portuguese hospital units (ULS Coimbra, ULS da Lezíria, ULS Loures-Odivelas). Pricing is not publicly disclosed but is positioned as cost-competitive and fixed-budget, leveraging Portugal's cost base relative to Western Europe and the US. Go-to-market is consultative and relationship-driven — direct enterprise engagement with R&D teams, conference participation (PEGS Europe, BIOSPAIN, ATMP Summit, EATRIS events), consortium membership (5 named consortia including CoroPrevention, LiverTarget, Bio-Hub, PRR, Mission Interface), and EIC Service Catalogue positioning targeting EU-funded early-stage developers. The company is co-led by Co-CEOs Ana Custódio and Francisco Castro and lists over 50 client and partner organisations including MSD, Labcorp, Eurofins, SGS, Technophage, Atreca, Fundação Champalimaud, and AICIB.

Short descriptiontext

VectorB2B is a Lisbon-based full-service Contract Research Organisation (CoLAB) providing integrated drug development services — from discovery and GLP toxicology through GMP manufacturing to Phase I–IV clinical trials — for biotech and pharma sponsors across Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLisbon, Portugal
HQ citystring
Lisbon
HQ countrystring
Portugal
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, drug development services, preclinical toxicology, clinical research services, pharmaceutical chemistry manufacturing
Industry3 codes
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1CRO Preclinical Services
TypeProfessional Services
Description

Fee-for-service preclinical research contracts encompassing discovery, GLP toxicology studies, bioanalysis, and pharmacology studies conducted at the Portugal-based facility. Revenue is generated on a per-study or fixed-budget basis.

vectorb2b.com
2GMP Manufacturing Services
TypeManaged Services
Description

Manufacturing of biologic medicines and Investigational Medicinal Products (IMPs) for clinical trial supply, GMP-certified, with particular strength in phage therapies. Revenue generated through manufacturing contracts with biotech and pharma sponsors.

vectorb2b.com
3Clinical Trial Management Services
TypeProfessional Services
Description

Full-service CRO support across phases I–IV, encompassing project management, monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory affairs, and site coordination. Billed through study contracts with pharmaceutical and biotech sponsors.

vectorb2b.com
4Functional Service Providing (FSP)
TypeProfessional Services
Description

Dedicated study coordinators and operational support for hospital investigation centres, including site feasibility, patient recruitment oversight, CRF data management, regulatory and contract management, and grant management. Revenue through service agreements with hospitals and clinical research sites.

vectorb2b.com
5R&D Portfolio Management Consulting
TypeProfessional Services
Description

Strategic consulting for R&D portfolio optimisation, including reformulation, repurposing, new product development and go-to-market strategy for drug development programmes.

vectorb2b.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

VectorB2B is a Contract Research Organization (CRO) structured as a Portuguese CoLAB (collaborative laboratory) that provides integrated drug development services to pharmaceutical and biotechnology clients. Its offerings span discovery, GLP-certified toxicology, GMP-certified chemistry manufacturing, clinical services, functional service providing, R&D portfolio management, and end-to-end integrated solutions across the development lifecycle.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Only in vivo TOX GLP-certified facility in Portugal
+1 more record
Product overview1 text field

VectorB2B is a full-service Contract Research Organization (CRO) providing integrated drug development services from bench to bedside. The company offers a comprehensive portfolio of services including Discovery, GLP/Non-GLP Toxicology (the only GLP-certified in vivo facility in Portugal), GMP-certified Chemistry Manufacturing (specializing in biologics and phage therapies), full Clinical Services (Phase I-IV), Functional Service Providing for hospital research centers, R&D Portfolio Management, and Integrated Solutions spanning medical devices, human health, animal health, cosmetics, cannabis, and food supplements. Supporting these services is a proprietary Technology Suite including CTMS, RTSM, eTMF, EDC, ePRO/eCOA, and eConsent platforms.

Product and service7 records
1Discovery Services
CategoryPreclinical Research
Description

Early-stage drug discovery research services supporting pharmaceutical and biotechnology sponsors in identifying and advancing candidate molecules.

2Toxicology Services
CategoryPreclinical Research
Description

GLP-certified toxicology studies conducted to regulatory standards to support drug development and safety assessment programs.

3Chemistry Manufacturing Services
CategoryPharmaceutical Manufacturing
Description

GMP-certified chemistry manufacturing services for drug substances and related chemical work supporting pharmaceutical development programs.

4Clinical Services
CategoryClinical Research
Description

Clinical research services supporting the execution of clinical trials as part of integrated drug development programs.

5Functional Service Providing (FSP)
CategoryResearch Services
Description

Functional service provision model offering dedicated resourcing and operational support for client R&D functions across the drug development lifecycle.

6R&D Portfolio Management
CategoryResearch Services
Description

Strategic management of client R&D portfolios, providing oversight and coordination of multi-program development activities.

7Integrated Solutions
CategoryDrug Development Services
Description

End-to-end integrated drug development solutions that combine discovery, preclinical, manufacturing, and clinical services into a single coordinated program for sponsors.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership22 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

AICIB (Associção para Investigação e Inovação em Biomedicina) is listed as a client and partner, representing a national biomedical research association that collaborates with VectorB2B on drug development programmes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

EATRIS (European Research Infrastructure for Translational Medicine) is a key partner, with VectorB2B co-hosting the EATRIS Spotlight Programme Portugal workshop on transition from preclinical to clinical trials in May 2025.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

ULS Coimbra (Unidade Local de Saúde de Coimbra) is a clinical partner, collaborating with VectorB2B and IdiPAZ to co-host the EATRIS Spotlight Programme workshop in 2025.

4ULS da Lezíria
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ULS da Lezíria is a co-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), alongside Escola Superior de Saúde de Santarém and RISE Health.

vectorb2b.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ULS Loures-Odivelas is a key clinical research partner, with its coordinator Susana Saraiva publicly endorsing VectorB2B's clinical trial outsourcing services as critical to expanding the unit's research productivity.

6Escola Superior de Saúde de Santarém
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), focused on strengthening clinical research ecosystems through structured dialogue.

vectorb2b.com
7RISE Health
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), bringing institutional experience from multiple ULS units to the programme.

vectorb2b.com
8SmartBio Analytics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership aimed at identifying and referring clients who can benefit from VectorB2B's integrated drug development services and SmartBio Analytics' bioanalytical expertise. Partners will jointly explore new business opportunities by scouting companies and institutions with early-stage development projects and actively collaborate on research projects leveraging complementary capabilities.

vectorb2b.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Labfit to advance research, strengthening joint commitment to meeting the evolving needs of the research community and critical projects in health innovation.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

VectorB2B partners with ISEG Executive Education in the Postgraduate Programme in Healthcare & Well-Being Management, combining academic expertise with real-world management challenges to equip healthcare professionals.

Strategic tierCoreTypeTechnology or Integration
Description

FASLAB is a member of the VectorB2B association contributing the in vivo phage display platform for antibody selection and targeted drug development. Applications in neurological diseases (blood-brain barrier crossing) and oncology.

Strategic tierMinorTypeOthers
Description

Listed as a client/partner with an interest in VectorB2B's integrated drug development services.

13Atreca
Strategic tierMinorTypeOthers
Description

Listed as a client and partner, representing a biotechnology company engaged with VectorB2B's CRO services.

vectorb2b.com
14Fundação Champalimaud
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a client and partner, representing a leading Portuguese biomedical research foundation with active collaboration interests in drug development.

vectorb2b.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a client and partner, representing a biotech company developing brain-delivery technologies with potential collaboration on drug development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Listed as a client and partner, representing Portugal's national health innovation cluster, of which VectorB2B is an active member.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a client and partner, representing Portugal's pharmaceutical and biotechnology industry association.

18CoroPrevention Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VectorB2B participates in the CoroPrevention research consortium focused on cardiovascular prevention, supporting drug development activities within the consortium framework.

vectorb2b.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VectorB2B participates in the LiverTarget research consortium focused on liver disease therapeutics, supporting drug development within the consortium.

20Bio-Hub Consortium
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VectorB2B participates in the Bio-Hub consortium, a Portuguese initiative supporting biotechnology and life sciences innovation.

vectorb2b.com
21Portuguese Recovery and Resilience Plan (PRR)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VectorB2B participates in the Portuguese Recovery and Resilience Plan (PRR) as part of the national innovation ecosystem, with funding and structural support for health R&D activities.

vectorb2b.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

VectorB2B participates in the Mission Interface programme, a Portuguese initiative bridging research institutions and industry to accelerate technology transfer and innovation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

Portugal-based CDMO with global operations, specializing in drug substance and particle engineering. Hovione is the most prominent Portuguese contract pharmaceutical services peer, anchoring the same national innovation ecosystem as VectorB2B and serving overlapping biotech clients.

TypeDirect peer
Description

Global testing, inspection, and certification company with significant life sciences and clinical research services. Listed as a client/partner on VectorB2B's website. SGS provides preclinical toxicology, bioanalytical, and clinical CRO services that overlap with VectorB2B's full-service offering.

TypeBroad incumbent
Description

World's largest CRO and healthcare data analytics provider. Offers comprehensive clinical, commercial, and real-world evidence services. Functions as a broad incumbent versus VectorB2B's boutique full-service model, competing for biotech sponsor mandates.

TypeBroad incumbent
Description

Global biopharmaceutical solutions organization offering clinical CRO and commercial services. Comparable as a broad incumbent clinical CRO competing with VectorB2B for Phase I-IV biotech mandates.

TypeDirect peer
Description

Global CRO and bioanalytical testing services provider listed as a client/partner on VectorB2B's website. Eurofins operates across pharmaceutical discovery, preclinical, and central laboratory services, directly overlapping with VectorB2B's GLP toxicology, bioanalysis, and clinical trial testing offerings.

TypeEmerging player
Description

Mid-sized global CRO with strong preclinical toxicology, bioanalysis, and translational medicine capabilities. Comparable to VectorB2B in service breadth and therapeutic-area focus (notably neuroscience and ophthalmology), though with broader geographic reach.

TypeDirect peer
Description

Major preclinical CRO with deep expertise in GLP toxicology, in vivo research models, and discovery services — directly comparable to VectorB2B's preclinical and toxicology core. Operates at global scale versus VectorB2B's Portugal-centric delivery.

TypeDirect peer
Description

Global CRO/CDMO offering integrated drug discovery, preclinical toxicology, CMC, and clinical services. Highly comparable to VectorB2B's integrated one-stop-shop model, with deeper geographic reach and scale.

TypeDirect peer
Description

Global clinical CRO providing full-service clinical trial management, biostatistics, data management, and pharmacovigilance across Phase I-IV. Directly comparable to VectorB2B's clinical services offering and eSuite technology stack.

TypeDirect peer
Description

Major global CRO (formerly Covance) offering preclinical toxicology, central labs, and clinical trial services. Listed as a client/partner on VectorB2B's website. Labcorp directly competes in VectorB2B's core GLP toxicology and clinical CRO categories, though at vastly larger scale.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

VectorB2B

Contract Research Servicesvectorb2b.com

VectorB2B is a Lisbon-based full-service Contract Research Organisation (CoLAB) providing integrated drug development services — from discovery and GLP toxicology through GMP manufacturing to Phase I–IV clinical trials — for biotech and pharma sponsors across Europe.

What VectorB2B does

VectorB2B – Drug Developing – Association for Research in Biotechnology is a Lisbon-headquartered, privately constituted Portuguese association (CoLAB) operating as a full-service Contract Research Organisation (CRO). It serves biotechnology and pharmaceutical companies requiring integrated drug development support from preclinical discovery through clinical trials Phase I–IV, as well as Portuguese hospital investigation centres needing embedded study coordination and regulatory support. Its service portfolio covers discovery, GLP/non-GLP toxicology, GMP-certified chemistry manufacturing and controls (with particular strength in biologic medicines and phage therapies), full-service clinical trial management, functional service providing (FSP) for hospitals, R&D portfolio management consulting, and integrated solutions spanning medical devices, animal health, cosmetics, cannabis, and food supplements. The company holds the only GLP-certified in vivo toxicology facility in Portugal and operates a GMP-certified manufacturing plant for Investigational Medicinal Products.

Underlying the service offering is a proprietary clinical trial technology suite (eSuite) comprising CTMS, RTSM, eTMF, EDC, ePRO/eCOA, eConsent, and wearables/device integration, complemented by specialised preclinical platforms including in vivo phage display (via member FASLAB), drug immunogenicity assessment using FO-SPR and cell-based NAb assays, cell-derived and patient-derived xenograft models, and in vivo retinal disease research models. The business model is fee-for-service and managed-service contracts with biotech and pharma sponsors, supplemented by FSP agreements with Portuguese hospital units (ULS Coimbra, ULS da Lezíria, ULS Loures-Odivelas). Pricing is not publicly disclosed but is positioned as cost-competitive and fixed-budget, leveraging Portugal's cost base relative to Western Europe and the US. Go-to-market is consultative and relationship-driven — direct enterprise engagement with R&D teams, conference participation (PEGS Europe, BIOSPAIN, ATMP Summit, EATRIS events), consortium membership (5 named consortia including CoroPrevention, LiverTarget, Bio-Hub, PRR, Mission Interface), and EIC Service Catalogue positioning targeting EU-funded early-stage developers. The company is co-led by Co-CEOs Ana Custódio and Francisco Castro and lists over 50 client and partner organisations including MSD, Labcorp, Eurofins, SGS, Technophage, Atreca, Fundação Champalimaud, and AICIB.

VectorB2B firmographics

Firmographics
Name
VectorB2B
Legal name
VectorB2B – Drug Developing – Association for Research in Biotechnology
Website
https://vectorb2b.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
VectorB2B is a Lisbon-based full-service Contract Research Organisation (CoLAB) providing integrated drug development services — from discovery and GLP toxicology through GMP manufacturing to Phase I–IV clinical trials — for biotech and pharma sponsors across Europe.
Ownership category
akta.pro rank

VectorB2B industry classification

Industry
Product category
Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAAAF
Clinical Data Management, Biostatistics & Statistical Programming CROs

Keywords

  • Contract research services
  • Drug development services
  • Preclinical toxicology
  • Clinical research services
  • Pharmaceutical chemistry manufacturing

Where VectorB2B is headquartered

Location

Headquarters

HQ city
Lisbon
HQ country
Portugal
HQ region
Europe

Offices1 record

Markets served

VectorB2B business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. CRO Preclinical Services: Fee-for-service preclinical research contracts encompassing discovery, GLP toxicology studies, bioanalysis, and pharmacology studies conducted at the Portugal-based facility. Revenue is generated on a per-study or fixed-budget basis.
  2. GMP Manufacturing Services: Manufacturing of biologic medicines and Investigational Medicinal Products (IMPs) for clinical trial supply, GMP-certified, with particular strength in phage therapies. Revenue generated through manufacturing contracts with biotech and pharma sponsors.
  3. Clinical Trial Management Services: Full-service CRO support across phases I–IV, encompassing project management, monitoring, data management, biostatistics, medical writing, pharmacovigilance, regulatory affairs, and site coordination. Billed through study contracts with pharmaceutical and biotech sponsors.
  4. Functional Service Providing (FSP): Dedicated study coordinators and operational support for hospital investigation centres, including site feasibility, patient recruitment oversight, CRF data management, regulatory and contract management, and grant management. Revenue through service agreements with hospitals and clinical research sites.
  5. R&D Portfolio Management Consulting: Strategic consulting for R&D portfolio optimisation, including reformulation, repurposing, new product development and go-to-market strategy for drug development programmes.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

VectorB2B product offering

Product offering

Core offering

VectorB2B is a Contract Research Organization (CRO) structured as a Portuguese CoLAB (collaborative laboratory) that provides integrated drug development services to pharmaceutical and biotechnology clients. Its offerings span discovery, GLP-certified toxicology, GMP-certified chemistry manufacturing, clinical services, functional service providing, R&D portfolio management, and end-to-end integrated solutions across the development lifecycle.

Product overview

VectorB2B is a full-service Contract Research Organization (CRO) providing integrated drug development services from bench to bedside. The company offers a comprehensive portfolio of services including Discovery, GLP/Non-GLP Toxicology (the only GLP-certified in vivo facility in Portugal), GMP-certified Chemistry Manufacturing (specializing in biologics and phage therapies), full Clinical Services (Phase I-IV), Functional Service Providing for hospital research centers, R&D Portfolio Management, and Integrated Solutions spanning medical devices, human health, animal health, cosmetics, cannabis, and food supplements. Supporting these services is a proprietary Technology Suite including CTMS, RTSM, eTMF, EDC, ePRO/eCOA, and eConsent platforms.

Differentiator

Problem solved

Functional benefit

Products and services

  • Discovery Services Early-stage drug discovery research services supporting pharmaceutical and biotechnology sponsors in identifying and advancing candidate molecules.
  • Toxicology Services GLP-certified toxicology studies conducted to regulatory standards to support drug development and safety assessment programs.
  • Chemistry Manufacturing Services GMP-certified chemistry manufacturing services for drug substances and related chemical work supporting pharmaceutical development programs.
  • Clinical Services Clinical research services supporting the execution of clinical trials as part of integrated drug development programs.
  • Functional Service Providing (FSP) Functional service provision model offering dedicated resourcing and operational support for client R&D functions across the drug development lifecycle.
  • R&D Portfolio Management Strategic management of client R&D portfolios, providing oversight and coordination of multi-program development activities.
  • Integrated Solutions End-to-end integrated drug development solutions that combine discovery, preclinical, manufacturing, and clinical services into a single coordinated program for sponsors.

Quantifiable outcome

  • Only in vivo TOX GLP-certified facility in Portugal
  • +1 more outcomes

Companies that use VectorB2B

Customer profile

Named customers11 records

Segments5 records

Ideal customer profiles1 record

VectorB2B technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

VectorB2B partnerships and signals

Strategic signal

Partnerships

22 partnerships are on record, tiered core and minor.

  • AICIBcoreStrategic or Co-development PartnerAICIB (Associção para Investigação e Inovação em Biomedicina) is listed as a client and partner, representing a national biomedical research association that collaborates with VectorB2B on drug development programmes.
  • EATRIScoreStrategic or Co-development PartnerEATRIS (European Research Infrastructure for Translational Medicine) is a key partner, with VectorB2B co-hosting the EATRIS Spotlight Programme Portugal workshop on transition from preclinical to clinical trials in May 2025.
  • ULS CoimbracoreStrategic or Co-development PartnerULS Coimbra (Unidade Local de Saúde de Coimbra) is a clinical partner, collaborating with VectorB2B and IdiPAZ to co-host the EATRIS Spotlight Programme workshop in 2025.
  • ULS da LezíriacoreStrategic or Co-development PartnerULS da Lezíria is a co-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), alongside Escola Superior de Saúde de Santarém and RISE Health.
  • ULS Loures-OdivelascoreStrategic or Co-development PartnerULS Loures-Odivelas is a key clinical research partner, with its coordinator Susana Saraiva publicly endorsing VectorB2B's clinical trial outsourcing services as critical to expanding the unit's research productivity.
  • Escola Superior de Saúde de SantarémcoreStrategic or Co-development PartnerCo-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), focused on strengthening clinical research ecosystems through structured dialogue.
  • RISE HealthcoreStrategic or Co-development PartnerCo-organiser of the VectorB2B Symposium on Value Proposition in Clinical Research (April 2026), bringing institutional experience from multiple ULS units to the programme.
  • SmartBio AnalyticscoreStrategic or Co-development PartnerStrategic partnership aimed at identifying and referring clients who can benefit from VectorB2B's integrated drug development services and SmartBio Analytics' bioanalytical expertise. Partners will jointly explore new business opportunities by scouting companies and institutions with early-stage development projects and actively collaborate on research projects leveraging complementary capabilities.
  • LabfitminorStrategic or Co-development PartnerCollaboration with Labfit to advance research, strengthening joint commitment to meeting the evolving needs of the research community and critical projects in health innovation.
  • ISEG Executive EducationminorStrategic or Co-development PartnerVectorB2B partners with ISEG Executive Education in the Postgraduate Programme in Healthcare & Well-Being Management, combining academic expertise with real-world management challenges to equip healthcare professionals.
  • FASLABcoreTechnology or IntegrationFASLAB is a member of the VectorB2B association contributing the in vivo phage display platform for antibody selection and targeted drug development. Applications in neurological diseases (blood-brain barrier crossing) and oncology.
  • AktheliaminorOthersListed as a client/partner with an interest in VectorB2B's integrated drug development services.
  • AtrecaminorOthersListed as a client and partner, representing a biotechnology company engaged with VectorB2B's CRO services.
  • Fundação ChampalimaudcoreStrategic or Co-development PartnerListed as a client and partner, representing a leading Portuguese biomedical research foundation with active collaboration interests in drug development.
  • Gate2BrainminorStrategic or Co-development PartnerListed as a client and partner, representing a biotech company developing brain-delivery technologies with potential collaboration on drug development.
  • Health-Cluster-PortugalcoreStrategic or Co-development PartnerListed as a client and partner, representing Portugal's national health innovation cluster, of which VectorB2B is an active member.
  • P-BiominorStrategic or Co-development PartnerListed as a client and partner, representing Portugal's pharmaceutical and biotechnology industry association.
  • CoroPrevention ConsortiumcoreStrategic or Co-development PartnerVectorB2B participates in the CoroPrevention research consortium focused on cardiovascular prevention, supporting drug development activities within the consortium framework.
  • LiverTarget ConsortiumcoreStrategic or Co-development PartnerVectorB2B participates in the LiverTarget research consortium focused on liver disease therapeutics, supporting drug development within the consortium.
  • Bio-Hub ConsortiumcoreStrategic or Co-development PartnerVectorB2B participates in the Bio-Hub consortium, a Portuguese initiative supporting biotechnology and life sciences innovation.
  • Portuguese Recovery and Resilience Plan (PRR)coreStrategic or Co-development PartnerVectorB2B participates in the Portuguese Recovery and Resilience Plan (PRR) as part of the national innovation ecosystem, with funding and structural support for health R&D activities.
  • Mission Interface ProgrammecoreStrategic or Co-development PartnerVectorB2B participates in the Mission Interface programme, a Portuguese initiative bridging research institutions and industry to accelerate technology transfer and innovation.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

VectorB2B competitors and assessment

Company assessment

Regional players

  • Hovione: Portugal-based CDMO with global operations, specializing in drug substance and particle engineering. Hovione is the most prominent Portuguese contract pharmaceutical services peer, anchoring the same national innovation ecosystem as VectorB2B and serving overlapping biotech clients.

Direct peers

  • SGS: Global testing, inspection, and certification company with significant life sciences and clinical research services. Listed as a client/partner on VectorB2B's website. SGS provides preclinical toxicology, bioanalytical, and clinical CRO services that overlap with VectorB2B's full-service offering.
  • Eurofins Scientific: Global CRO and bioanalytical testing services provider listed as a client/partner on VectorB2B's website. Eurofins operates across pharmaceutical discovery, preclinical, and central laboratory services, directly overlapping with VectorB2B's GLP toxicology, bioanalysis, and clinical trial testing offerings.
  • Charles River Laboratories: Major preclinical CRO with deep expertise in GLP toxicology, in vivo research models, and discovery services — directly comparable to VectorB2B's preclinical and toxicology core. Operates at global scale versus VectorB2B's Portugal-centric delivery.
  • Pharmaron: Global CRO/CDMO offering integrated drug discovery, preclinical toxicology, CMC, and clinical services. Highly comparable to VectorB2B's integrated one-stop-shop model, with deeper geographic reach and scale.
  • ICON plc: Global clinical CRO providing full-service clinical trial management, biostatistics, data management, and pharmacovigilance across Phase I-IV. Directly comparable to VectorB2B's clinical services offering and eSuite technology stack.
  • Labcorp: Major global CRO (formerly Covance) offering preclinical toxicology, central labs, and clinical trial services. Listed as a client/partner on VectorB2B's website. Labcorp directly competes in VectorB2B's core GLP toxicology and clinical CRO categories, though at vastly larger scale.

Broad incumbents

  • IQVIA: World's largest CRO and healthcare data analytics provider. Offers comprehensive clinical, commercial, and real-world evidence services. Functions as a broad incumbent versus VectorB2B's boutique full-service model, competing for biotech sponsor mandates.
  • Syneos Health: Global biopharmaceutical solutions organization offering clinical CRO and commercial services. Comparable as a broad incumbent clinical CRO competing with VectorB2B for Phase I-IV biotech mandates.

Emerging players

  • QPS Holdings: Mid-sized global CRO with strong preclinical toxicology, bioanalysis, and translational medicine capabilities. Comparable to VectorB2B in service breadth and therapeutic-area focus (notably neuroscience and ophthalmology), though with broader geographic reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

VectorB2B social profiles

Digital presence

VectorB2B compliance and trust

Trust signal

Compliance2 records

VectorB2B financial estimates

Financial estimate

Revenue estimate

Valuation estimate

VectorB2B leadership team

Management profile

Number of profiles

Profiles2 records

VectorB2B funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

VectorB2B M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about VectorB2B

What does VectorB2B do?

VectorB2B is a Contract Research Organization (CRO) structured as a Portuguese CoLAB (collaborative laboratory) that provides integrated drug development services to pharmaceutical and biotechnology clients. Its offerings span discovery, GLP-certified toxicology, GMP-certified chemistry manufacturing, clinical services, functional service providing, R&D portfolio management, and end-to-end integrated solutions across the development lifecycle.

Is VectorB2B a public or private company?

VectorB2B is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was VectorB2B founded?

VectorB2B was founded in 2019. It employs 11 to 50 people.

Where is VectorB2B based?

VectorB2B is headquartered in Lisbon, Portugal, in the Europe region.

How does VectorB2B make money?

Five revenue lines are on record. CRO Preclinical Services are the primary driver. The others are GMP Manufacturing Services, clinical Trial Management Services, functional Service Providing (FSP) and R&D Portfolio Management Consulting.

Who are VectorB2B's main competitors?

Hovione is listed as a regional player. Direct peers are SGS, Eurofins Scientific, Charles River Laboratories, Pharmaron, ICON plc and Labcorp. Broad incumbents are IQVIA and Syneos Health. QPS Holdings is listed as an emerging player.

Does VectorB2B have an API?

No public API is recorded for VectorB2B.

What industry is VectorB2B in?

VectorB2B's product category is Contract Research Services. Its primary akta.pro industry code is HLAGAAAA, Clinical CROs (Phase I–IV), with a secondary code of HLAGAAAC, Toxicology & Safety Assessment CROs (GLP). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales